Update from Autifony Therapeutics’ QUIET-1 clinical trial

Autifony Therapeutics recruits first patient into Phase IIa trial for first-in-class drug to treat Age Related Hearing Loss. Study follows acceptance of Autifony’s first IND by the FDA

Autifony Therapeutics announces £3.3 million collaboration to progress first-in-class drug for schizophrenia into clinical trials

Autifony Therapeutics supports art exhibition ‘Reassembling the self’, focused on schizophrenia, together with Universities of Manchester and Newcastle

Autifony Therapeutics hosts symposium ‘Schizophrenia: a treatable brain disorder’ at British Association for Psychopharmacology